PubMed Health⌕ Search

Biomedical subjects

K Bitter

Publications and source records attributed to K Bitter.

At least 55 records · Page 3Linked to original sources
PubMed1977

Superadditive cytostatic effects after combined administration of vincristine, bleomycin and methotrexate to Yoshida sarcoma.

Vincristine, bleomycin and methotrexate are three cytostatic drugs which are particularly effective in epidermoid carcinoma of the head and neck region. As their dose-limiting side effects differ from one another, it appeared reasonable to combine them. To examine in vitro whether this combination increases cytostatic activity, the three drugs were administered to Yoshida sarcoma. It could be demonstrated that the growth inhibition activity and the cell disturbance activity were much higher with combination therapy than with single drug therapy. From this, it follows that beneficial results in the treatment of head and neck carcinomas can be expected.

Animals↗
PubMed1977

[Dentomaxillary destructions in oxalosis].

Oxalosis, a rare metabolic disorder, leads to excessive formation of oxalate and deposition of calcium oxalate crystals in the tissue. This leads to renal insufficiency with resulting secondary hyperparathyroidism and myelofibrosis. In a 27 year old female patient, extensive destruction of the maxilla, mandible and teeth was observed which has not yet been described and which led to the loss of all teeth.

Adult↗
PubMed1977

[Combination therapy by bleomycin, methotrexate, and telecobalt irradiation in carcinoma of the oral cavity (author's transl)].

20 patients with advanced carcinomas of the oral cavity (T3NxMo) were treated at the same time with the cytostatic drugs bleomycin and methotrexate as well as with a cobalt-60-irradiation. 14 of them are tumor free after an observation period of one half to two and a half years. Among them were 4 recurrences that had to be treated surgically. 1 patient is living with a residual tumor which cannot be further treated. 5 patients died of the tumor or of other causes. The survival rate, which is 80% after 1 year, is, as a tentative result, higher than could be attained by other therapeutic measures.

Adult↗
PubMed1976

Pharmacokinetic behaviour of bleomycin-cobalt-57 with special regard to intraarterial perfusion of the maxillo-facial region.

Bleomycin was traced by the isotope Cobalt-57. By using this radioactive substance the pharmacokinetic behaviour of the drug was examined. It was given either intravenously or intra-arterially or directly into the tumor in patients suffering from epidermoid carcinoma in the maxillo-facial region. The differences in the pharmacokinetic data are delineated. Practically, the intra-arterial route of administration is the best one because of the high adherence rate of the drug to the perfused tissue.

Bleomycin↗